Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sab Biotherapeutics Inc (SABS)

Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 197,690
  • Shares Outstanding, K 50,951
  • Annual Sales, $ 0 K
  • Annual Income, $ 13,270 K
  • EBIT $ -49 M
  • EBITDA $ -46 M
  • 60-Month Beta 0.60
  • Price/Sales N/A
  • Price/Cash Flow 11.33
  • Price/Book 1.22

Options Overview Details

View History
  • Implied Volatility 195.03% (-55.80%)
  • Historical Volatility 68.79%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 958.92% on 03/23/26
  • IV Low 195.03% on 04/02/26
  • Expected Move (DTE 13) 0.26 (6.57%)
  • Put/Call Vol Ratio 1.36
  • Today's Volume 52
  • Volume Avg (30-Day) 194
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 2,568
  • Open Int (30-Day) 2,051
  • Expected Range 3.63 to 4.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.16
  • Number of Estimates 2
  • High Estimate $-0.12
  • Low Estimate $-0.20
  • Prior Year $-0.56
  • Growth Rate Est. (year over year) +71.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.64 +6.59%
on 03/06/26
5.15 -24.66%
on 03/12/26
-0.19 (-4.67%)
since 03/02/26
3-Month
3.41 +13.78%
on 01/12/26
5.15 -24.66%
on 03/12/26
+0.11 (+2.92%)
since 01/02/26
52-Week
1.00 +288.00%
on 04/04/25
6.60 -41.21%
on 07/21/25
+2.63 (+210.40%)
since 04/02/25

Most Recent Stories

More News
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10,...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO to Participate in Upcoming Investor Conferences

MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:  SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO to Participate in Upcoming Investor Conferences

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ),...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

Enrollment in the SAFEGUARD trial is ongoing at multiple centers globally Company on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc....

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)

Business Summary

SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress...

See More

Key Turning Points

3rd Resistance Point 4.10
2nd Resistance Point 4.03
1st Resistance Point 3.96
Last Price 3.88
1st Support Level 3.82
2nd Support Level 3.75
3rd Support Level 3.68

See More

52-Week High 6.60
Fibonacci 61.8% 4.46
Last Price 3.88
Fibonacci 50% 3.80
Fibonacci 38.2% 3.14
52-Week Low 1.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.